| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.03 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.03 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.098 | 0.03 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.03 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.17 | 0.04 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.084 | 0.04 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | 0.33 | 0.04 |
| mRNA | JQ-1:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |